The BMJ

FDA is now “open to bayesian statistics”: transformational change or new Pandora’s box?

The US Food and Drug Administration (FDA) is now “open to bayesian statistics,” contrasting this with the frequentist approach that the agency and the drug industry have historically relied on for ...
JD Supra

FDA: Drug & Device Advisory | Frequentist or Bayesian? All Roads Lead to Smarter Trials with FDA’s New Bayesian Guidance

Jessica Ritsick, Yifan Wang, Ph.D. Our FDA: Drug & Device Team analyzes the Food and Drug Administration’s new guidance on Bayesian approaches to innovative drug trials, providing greater clarity on ...

One weird thing that’s been holding drug trials back

For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...
Nature

Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics

Pediatric clinical trials commonly experience recruitment challenges including limited number of patients and investigators, inclusion/exclusion criteria that further reduce the patient pool, and a ...
JSTOR Daily

DISCUSSION OF "FREQUENTIST COVERAGE OF ADAPTIVE NONPARAMETRIC BAYESIAN CREDIBLE SETS"

The Annals of Statistics publishes research papers of the highest quality reflecting the many facets of contemporary statistics. Primary emphasis is placed on importance and originality, not on ...